SweetValueLab
Write for us

Cencora, Inc. — Wall Street Analyst Estimates & Price Targets

COR
NYSEHealthcareMedical - DistributionCIK 0001140859cencora.comAbout COR
Last close · Oct 16, 2026340.92−0.49 (−0.14%)
Market cap$65.1B

5 firms' latest targets, last 90 days: median $350.00 ($330.00–$400.00), 3% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker
$250$300$350$400$450NovJan 2026MarMayJulSep2025-10-27 · UBS: $3802025-10-30 · Mizuho Securities: $3402025-11-06 · Evercore ISI: $4002025-11-07 · UBS: $4152025-12-08 · Barclays: $4002025-12-16 · Baird: $3922026-01-13 · Baird: $4152026-01-22 · Jefferies: $4402026-01-29 · Morgan Stanley: $4002026-02-05 · Evercore ISI: $4202026-02-10 · Wells Fargo: $4292026-02-13 · Barclays: $4252026-03-17 · Morgan Stanley: $3802026-04-08 · Evercore ISI: $3602026-05-07 · UBS: $4122026-05-08 · Morgan Stanley: $3422026-05-11 · Wells Fargo: $3312026-06-10 · Barclays: $3502026-08-06 · Baird: $3702026-08-06 · UBS: $4302026-08-06 · Evercore ISI: $3502026-08-07 · Morgan Stanley: $3462026-08-19 · RBC Capital: $3302026-10-16 · UBS: $400
$250$300$350$400$450NovFebMayAug

Each firm's latest target

last 90 days · 5 firms
DateFirmTargetPreviousChangeVs price thenVs price now
2026-10-16UBS$400.00$430.00▼ 7%+17%+17%
2026-08-19RBC Capital$330.00——+4%-3%
2026-08-07Morgan Stanley$346.00$342.00▲ 1%+7%+1%
2026-08-06Baird$370.00$415.00▼ 11%+18%+9%
2026-08-06Evercore ISI$350.00$360.00▼ 3%+10%+3%

Consensus estimates

revenue and EPS by fiscal year · reported years marked
FYRevenueYoYEPSYoYRevenue rangeEPS rangeAnalysts
2023reported$262.2B+10%$8.53+6%est. $259.7B+1%est. $11.938
2024reported$294.0B+12%$7.53-12%est. $310.2B-5%est. $8.664
2025reported$321.3B+9%$7.96+6%est. $321.0B+0%est. $15.949
2026$337.1B+5%$17.89+12%$337.0B–$337.4B$17.87–$17.929
2027$352.1B+4%$19.76+10%$349.9B–$354.9B$19.46–$20.106
2028$368.6B+5%$21.80+10%$355.9B–$379.3B$20.01–$23.866
2029$385.8B+5%$24.79+14%$368.6B–$397.7B$22.14–$26.293
2030$403.4B+5%$28.28+14%$393.1B–$411.3B$27.34–$29.001
A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.